Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in combination with obinutuzumab or venetoclax in CLL/SLL/PLL
NCT02296918Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Dec 2014
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and prolymphocytic leukemia (PLL) (4 cohorts), sponsored by Acerta Pharma. Primary endpoints: Objective Response Rate at 12 months, Treatment Emergent Adverse Events and 3 more. Started Dec 2014; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT02296918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296918.